Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma
Status:
Unknown status
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, single arm, open-label, prospective IIS study, which will enroll 40
recurrent MCL patients.The aim is to evaluate the efficacy and safety of bortezomib,
fludarabine and cyclophosphamide treatment and also analyze the relationship between NF-kB
activity and efficacy of bortezomib treatment and whether NF-kB activity can predict MCL
progression.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Beijing Cancer Hospital Fudan University Jiangsu Cancer Institute & Hospital Ruijin Hospital Tianjin Medical University Cancer Institute and Hospital West China Hospital Zhejiang University